A Study in Patients With Chorioretinal Vascular Disease to Evaluate an Aflibercept (EYLEA) Prefilled Syringe
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration; Diabetic macular oedema; Diabetic retinopathy; Retinal vein occlusion
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 04 Oct 2019 Planned number of patients changed from 35 to 70.
- 04 Oct 2019 Planned End Date changed from 22 Jan 2019 to 9 Mar 2020.
- 04 Oct 2019 Planned primary completion date changed from 22 Jan 2019 to 9 Mar 2020.